Physician profile
Michael Olay
NPI 1205801552
$9,865.14
in general payments reported to CMS, 2019-2025
36 companies · $1,019 in 2025
The $1,019 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,338 · 2020: $1,507 · 2021: $2,195 · 2022: $1,199 · 2023: $1,256 · 2024: $1,350 · 2025: $1,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,621 · Education: $5.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,620.88 |
| Education | $5.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $2,281.46 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,489.11 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $931.91 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $634.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $559.18 | 2019-2025 | Repatha, Otezla, Evenity |
| Amarin Pharma, INC. | $515.52 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $467.46 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $428.19 | 2019-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Abbvie INC. | $385.81 | 2020-2025 | |
| Lilly USA, LLC | $298.93 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $290.00 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $277.41 | 2020-2022 | |
| Abbott Laboratories | $259.99 | 2021-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $100.02 | 2023-2025 | Cologuard Collection Kit |
| Genentech USA, INC. | $82.10 | 2020-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $79.31 | 2022-2023 | Azstarys |
| Janssen Pharmaceuticals, INC | $78.61 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $77.51 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $62.29 | 2020-2021 | |
| Shire North American Group INC | $61.54 | 2019 | |
| Sanofi Pasteur INC. | $60.77 | 2019-2025 | |
| Paratek Pharmaceuticals, INC. | $56.20 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.15 | 2023-2024 | Xifaxan |
| Horizon Therapeutics Plc | $50.55 | 2020-2021 | |
| Eisai INC. | $49.23 | 2020-2021 | |
| Ultragenyx Pharmaceutical INC. | $38.80 | 2022-2023 | |
| Bausch Health US, LLC | $35.36 | 2020-2023 | Aplenzin, Wellbutrin |
| Nestle Healthcare Nutrition INC. | $26.46 | 2021 | |
| Ironshore Pharmaceuticals INC. | $26.15 | 2019 | |
| Corcept Therapeutics | $21.43 | 2025 | Korlym |
| Dexcom, INC. | $19.37 | 2021 | |
| Kaleo, INC. | $14.73 | 2022 | |
| Alexion Pharmaceuticals, INC. | $13.90 | 2021 | |
| Sobi, INC | $13.86 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $13.47 | 2022 | |
| Allergan, INC. | $11.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Olay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.